Skip to main content
Bristol Myers SquibbLaunch

Mavacamten gains FDA approval for symptomatic obstructive HCM in pediatric and adult patients

Source: Autobound Signal API · 117 signals tracked for Bristol Myers Squibb · updated

Get Bristol Myers Squibb's live signals in Claude or ChatGPT, or by API

AskWhat changed at Bristol Myers Squibb this week? Use Autobound signals for bms.com.

What happened

Bristol Myers Squibb's drug, mavacamten (Camzyos), received expanded FDA approval to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in both adult and pediatric patients.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Photo from AHA 2022. The U.S. Food and Drug Administration (FDA) expanded the indication for Bristol Myers Squibb's mavacamten (Camzyos) to improve functional capacity and symptoms in obstructive hypertrophic cardiomyopathy (oHCM) in both adult and pediatric patients. The company said this expanded indication offers a new treatment option for patients with a significant unmet need. Mavacamten first gained FDA clearance in April 2022 for adults with symptomatic NYHA class II-III oHCM heart failure, but the new indication will broaden the patient populations that can be treated. The indication also allows earlier interventions, rather than waiting for patient conditions to worsen over time. The drug is now the only FDA-approved therapy for the treatment of oHCM in a pediatric population. The FDA indication for children is for use in patients weighing 30 kg (66 lbs) or more. "Today's approval marks an important milestone for young patients and families who are facing a serious cardiovascular disease with significant unmet medical need," Al Reba, senior vice president, immunology and cardiovascular commercialization, Bristol Myers Squibb, said in a statement. "For young patients living with this disease, the burden on daily life can be substantial during a critical stage of development, and we are proud to help bring an innovative new treatment option to this community." The...

Keep reading with a free account

The rest of this article, and every signal for Bristol Myers Squibb, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Launch

What this signalsA launch often needs new go-to-market and support spend.

Product
mavacamten

More launch signals at other companies

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical

Extraction

Confidence
100%
Detected
Oct 1, 2026
signal_type
news
signal_subtype
launches

Use this data

Get every launch signal for Bristol Myers Squibb and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bristol Myers Squibb this week?”

  2. Send it to your own tools

    The Signal API returns launch signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/1be2c273-7ba4-3db0-0bbb-e4524507b353 returns this record as JSON. POST /v1/companies/enrich returns every signal for bms.com.

{
  "signal_id": "1be2c273-7ba4-3db0-0bbb-e4524507b353",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-10-01T15:35:05+00:00",
  "company": {
    "name": "Bristol Myers Squibb",
    "domain": "bms.com"
  },
  "data": {
    "url": "https://cardiovascularbusiness.com/topics/clinical/hypertrophic-cardiomyopathy-hcm/mavacamten-gains-fda-approval-symptomatic-obstructive-hcm-pediatric-and-adult-patients",
    "title": "Mavacamten gains FDA approval for symptomatic obstructive HCM in pediatric and adult patients - Cardiovascular Business",
    "excerpt": "Photo from AHA 2022. The U.S. Food and Drug Administration (FDA) expanded the indication for Bristol Myers Squibb’s mavacamten (Camzyos) to improve functional capacity and symptoms in obstructive hypertrophic cardiomyopathy (oHCM) in both adult and pediatric patients. The company said this expanded indication offers a new treatment option for patients with a significant unmet need. Mavacamten first gained FDA clearance in April 2022 for adults with symptomatic NYHA class II-III oHCM heart failure, but the new indication will broaden the patient populations that can be treated. The indication also allows earlier interventions, rather than waiting for patient conditions to worsen over time. The drug is now the only FDA-approved therapy for the treatment of oHCM in a pediatric population. The FDA indication for children is for use in patients weighing 30 kg (66 lbs) or more. “Today’s approval marks an important milestone for young patients and families who are facing a serious cardiovascular disease with significant unmet medical need,” Al Reba , senior vice president, immunology and cardiovascular commercialization, Bristol Myers Squibb, said in a statement. “For young patients living with this disease, the burden on daily life can be substantial during a critical stage of development, and we are proud to help bring an innovative new treatment option to this community.\" The FDA...",
    "product": "mavacamten",
    "summary": "Bristol Myers Squibb's drug, mavacamten (Camzyos), received expanded FDA approval to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in both adult and pediatric patients.",
    "planning": false,
    "image_url": "https://cardiovascularbusiness.com/sites/default/files/styles/facebook/public/2022-11/Camzyos%20mavacamten%20for%20HCM_AHA22_DF.jpeg_1.jpeg?h=71976bb4&itok=4osUpdUh",
    "confidence": 1,
    "product_data": {
      "name": "mavacamten",
      "full_text": "Bristol Myers Squibb’s mavacamten (Camzyos)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-01T15:35:05Z",
    "article_sentence": "The U.S. Food and Drug Administration (FDA) expanded the indication for Bristol Myers Squibb’s mavacamten (Camzyos) to improve functional capacity and symptoms in obstructive hypertrophic cardiomyopathy (oHCM) in both adult and pediatric patients."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.